Last reviewed · How we verify
Short DAPT
Short DAPT involves a reduced duration of dual antiplatelet therapy to minimize bleeding risks while maintaining cardiovascular protection.
Short DAPT involves a reduced duration of dual antiplatelet therapy to minimize bleeding risks while maintaining cardiovascular protection. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome.
At a glance
| Generic name | Short DAPT |
|---|---|
| Also known as | 3 months ASA + Clopidogrel |
| Sponsor | Korea University Guro Hospital |
| Drug class | Antiplatelet |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Short DAPT typically involves a shorter duration of dual antiplatelet therapy compared to standard DAPT, which can reduce the risk of bleeding complications while still providing adequate cardiovascular protection. This approach is often used in patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
Approved indications
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Acute kidney injury
Key clinical trials
- PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
- OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- OCT-based DAPT Cessation in HBR Patients (NA)
- Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI (PHASE3)
- Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients (PHASE4)
- Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy (NA)
- Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Short DAPT CI brief — competitive landscape report
- Short DAPT updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI